On April 11th 2005, I founded Aqumen Biopharmaceuticals with the mission to eradicate blindness.
Soon after founding Aqumen, I set up a US operation which quickly expanded to India and Europe. During this time, I was faced with manydifficult decisions however, inspired by our mission and with the helpof a dedicated management team, I managed to overcome the many obstacles which stood in our way.
On September 27th 2010, we finally achieved our goal to launch ourfirst product. This product also marked the first product based on technology discovered, researched and developed by a Japanese Biotech company. Today, we are marketing the product---ILM Blue (API: BBG250), all over Europe with the help of our Dutch partner DORC (Dutch Ophthalmic Research Center)
Together we have shown that:
１．There are exiting scientific technologies being discovered in Japan.
２. Under the right leadership, these technologies can be commercialized and developed into a successful global business.
The world is very different now. Japan has lost its leadership in many different areas. In the short term, we face many difficult challenges, however in the long term, I believe that we may benefit from these difficulties which we currently face. It has been said that the Japanese people by nature tend to be inward looking. At present however, we have no other choice than to develop technologies and human resources throughout the global community. This situation is surely encouraging the younger generation to grow in the global context.
Today is just the beginning of our new journey. With Japanese cutting edge technologies as our core focus, we will continue to develop technologies to build a successful global business and complete our mission.
- Hardy TS Kagimoto, M.D.
CEO & President of Aqumen Biopharmaceuticals K.K.
Chairman of Aqumen Biopharmaceuticals NA, Inc